- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
Latest News
Days after the Indian Council of Medical Research (ICMR) dropped usage of convalescent plasma from recommended treatment...
Read More
Read More
Levels of antibodies produced to fight off the virus are 20% to 300% higher when the follow-up vaccine comes later, new...
Read More
Read More
Scientists are calling for ventilation systems to be overhauled like public water supplies were in the 1800s after fetid...
Read More
Read More
The lab-based study was carried out by the NYU Grossman School of Medicine and NYU Langone Center and is considered...
Read More
Read More
The international scheme to ensure equal access to Covid-19 vaccines is 140 million doses short because of India's...
Read More
Read More
The first batch of anti-COVID drug 2-DG, developed by the Defence Research and Development Organisation (DRDO), will be...
Read More
Read More
The World Health Organization said Wednesday that a variant of Covid-19 behind the acceleration of India’s explosive...
Read More
Read More
In a choked voice, Parasuram Maurya described desperately running from one hospital to another to save his...
Read More
Read More
#In just 42 days, more than 2.6 lakh people donated enough money to pay for the one-time gene therapy Zolgensma for...
Read More
Read More
Biden had been under intense pressure to waive protections for vaccine manufacturers, especially amid criticism that...
Read More
Read More
Prashant Tandon, founder and CEO of 1mg, said they have roped in 600 corporates as partners and are now in talks with...
Read More
Read More
The government said on Wednesday a third phase of the coronavirus is inevitable, but it is not clear on what time scale...
Read More
Read More